Report error Found 42 Enz. Inhib. hit(s) with all data for entry = 12726
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Zhejiang Hisun Pharmaceutical
US Patent
Zhejiang Hisun Pharmaceutical
US Patent
Affinity DataIC50: 0.600nMAssay Description:The experimental steps are as follows:(1) The test compound (the compound of the present disclosure, and compound 164 in WO2018017983A1 as a control)...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Zhejiang Hisun Pharmaceutical
US Patent
Zhejiang Hisun Pharmaceutical
US Patent
Affinity DataIC50: 1.40nMAssay Description:The experimental steps are as follows:(1) The test compound (the compound of the present disclosure, and compound 164 in WO2018017983A1 as a control)...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Zhejiang Hisun Pharmaceutical
US Patent
Zhejiang Hisun Pharmaceutical
US Patent
Affinity DataIC50: 1.5nMAssay Description:The experimental steps are as follows:(1) The test compound (the compound of the present disclosure, and compound 164 in WO2018017983A1 as a control)...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Zhejiang Hisun Pharmaceutical
US Patent
Zhejiang Hisun Pharmaceutical
US Patent
Affinity DataIC50: 1.70nMAssay Description:The experimental steps are as follows:(1) The test compound (the compound of the present disclosure, and compound 164 in WO2018017983A1 as a control)...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Zhejiang Hisun Pharmaceutical
US Patent
Zhejiang Hisun Pharmaceutical
US Patent
Affinity DataIC50: 1.80nMAssay Description:The experimental steps are as follows:(1) The test compound (the compound of the present disclosure, and compound 164 in WO2018017983A1 as a control)...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Zhejiang Hisun Pharmaceutical
US Patent
Zhejiang Hisun Pharmaceutical
US Patent
Affinity DataIC50: 2nMAssay Description:The experimental steps are as follows:(1) The test compound (the compound of the present disclosure, and compound 164 in WO2018017983A1 as a control)...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Zhejiang Hisun Pharmaceutical
US Patent
Zhejiang Hisun Pharmaceutical
US Patent
Affinity DataIC50: 2.60nMAssay Description:The experimental steps are as follows:(1) The test compound (the compound of the present disclosure, and compound 164 in WO2018017983A1 as a control)...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Zhejiang Hisun Pharmaceutical
US Patent
Zhejiang Hisun Pharmaceutical
US Patent
Affinity DataIC50: 3nMAssay Description:The experimental steps are as follows:(1) The test compound (the compound of the present disclosure, and compound 164 in WO2018017983A1 as a control)...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Zhejiang Hisun Pharmaceutical
US Patent
Zhejiang Hisun Pharmaceutical
US Patent
Affinity DataIC50: 3.90nMAssay Description:The experimental steps are as follows:(1) The test compound (the compound of the present disclosure, and compound 164 in WO2018017983A1 as a control)...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Zhejiang Hisun Pharmaceutical
US Patent
Zhejiang Hisun Pharmaceutical
US Patent
Affinity DataIC50: 5.60nMAssay Description:The experimental steps are as follows:(1) The test compound (the compound of the present disclosure, and compound 164 in WO2018017983A1 as a control)...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Zhejiang Hisun Pharmaceutical
US Patent
Zhejiang Hisun Pharmaceutical
US Patent
Affinity DataIC50: 6.20nMAssay Description:The experimental steps are as follows:(1) The test compound (the compound of the present disclosure, and compound 164 in WO2018017983A1 as a control)...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Zhejiang Hisun Pharmaceutical
US Patent
Zhejiang Hisun Pharmaceutical
US Patent
Affinity DataIC50: 7.30nMAssay Description:The experimental steps are as follows:(1) The test compound (the compound of the present disclosure, and compound 164 in WO2018017983A1 as a control)...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Zhejiang Hisun Pharmaceutical
US Patent
Zhejiang Hisun Pharmaceutical
US Patent
Affinity DataIC50: 8nMAssay Description:The experimental steps are as follows:(1) The test compound (the compound of the present disclosure, and compound 164 in WO2018017983A1 as a control)...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Zhejiang Hisun Pharmaceutical
US Patent
Zhejiang Hisun Pharmaceutical
US Patent
Affinity DataIC50: 8.10nMAssay Description:The experimental steps are as follows:(1) The test compound (the compound of the present disclosure, and compound 164 in WO2018017983A1 as a control)...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Zhejiang Hisun Pharmaceutical
US Patent
Zhejiang Hisun Pharmaceutical
US Patent
Affinity DataIC50: 8.60nMAssay Description:The experimental steps are as follows:(1) The test compound (the compound of the present disclosure, and compound 164 in WO2018017983A1 as a control)...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Zhejiang Hisun Pharmaceutical
US Patent
Zhejiang Hisun Pharmaceutical
US Patent
Affinity DataIC50: 10.3nMAssay Description:The experimental steps are as follows:(1) The test compound (the compound of the present disclosure, and compound 164 in WO2018017983A1 as a control)...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Zhejiang Hisun Pharmaceutical
US Patent
Zhejiang Hisun Pharmaceutical
US Patent
Affinity DataIC50: 11.8nMAssay Description:The experimental steps are as follows:(1) The test compound (the compound of the present disclosure, and compound 164 in WO2018017983A1 as a control)...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Zhejiang Hisun Pharmaceutical
US Patent
Zhejiang Hisun Pharmaceutical
US Patent
Affinity DataIC50: 12.5nMAssay Description:The experimental steps are as follows:(1) The test compound (the compound of the present disclosure, and compound 164 in WO2018017983A1 as a control)...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Zhejiang Hisun Pharmaceutical
US Patent
Zhejiang Hisun Pharmaceutical
US Patent
Affinity DataIC50: 24.7nMAssay Description:The experimental steps are as follows:(1) The test compound (the compound of the present disclosure, and compound 164 in WO2018017983A1 as a control)...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Zhejiang Hisun Pharmaceutical
US Patent
Zhejiang Hisun Pharmaceutical
US Patent
Affinity DataIC50: 25.6nMAssay Description:The experimental steps are as follows:(1) The test compound (the compound of the present disclosure, and compound 164 in WO2018017983A1 as a control)...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Zhejiang Hisun Pharmaceutical
US Patent
Zhejiang Hisun Pharmaceutical
US Patent
Affinity DataIC50: 73nMAssay Description:The experimental steps are as follows:(1) The test compound (the compound of the present disclosure, and compound 164 in WO2018017983A1 as a control)...More data for this Ligand-Target Pair




















